Tracers / [177Lu]Lu-DOTA-His-His-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2
[177Lu]Lu-DOTA-His-His-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2
Also written as [Lu-177]Lu-DOTA-His-His-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Minigastrin analogue (DOTA-conjugated peptide, CCK2/gastrin receptor-binding)
- Target / mechanism
- —
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | 90 | 99 | DOTA-H2MG11 piCHEM, Raaba-Grambach, Austria | 31526356 2020 Curr Radiopharm The labelling reactions were performed by addition of 605 µL of the corresponding buffer-stabilizer mixture — reaching 90% of LMG, 1-2% of LMG-Met(O) and 8-7% of peptide impurities |
Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-His-His-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 31526356. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 31526356: 'DOTA APH070 Minigastrin (DOTA-H2MG11) = (DOTA-His-His-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) as its TFA salt was obtained from piCHEM'.